scPharmaceuticals (SCPH) Leerink’s Global Healthcare Conference 2025 summary

Strategic focus and product overview

• Focused on shifting care from hospitals to home settings for better outcomes and lower costs.

• FUROSCIX delivers IV-strength furosemide subcutaneously at home, targeting heart failure and chronic kidney disease (CKD) patients.

• Expanded label now covers edema from both heart failure and CKD, broadening the addressable market.

• Product feedback highlights reliability, rapid action, and predictable results.

Key 2025 priorities and catalysts

• Recent label expansion to CKD opens access to 700,000 new patients and nephrology market.

• Launch in nephrology set for mid-April, with expanded sales force supporting growth.

• Medicare redesign lowers patient out-of-pocket caps, improving affordability and access.

• NDA filing for an autoinjector planned mid-year, with launch expected in the first half of next year.

Market access, sales, and distribution

• 70-75% of patients are on Medicare, with the rest split between Medicaid and commercial plans.

• Copay smoothing and $2,000 out-of-pocket cap expected to drive prescription volume increases by April-May.

• Specialty pharmacy network expanded for faster, more accessible home delivery.

• Direct relationships established with major IDNs and health systems, including Kaiser and Cleveland Clinic.